Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In lupus animal models, the Janus kinase (JAK) inhibitor tofacitinib improves clinical fea...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasni, Sarfaraz A., Gupta, Sarthak, Davis, Michael, Poncio, Elaine, Temesgen-Oyelakin, Yenealem, Carlucci, Philip M., Wang, Xinghao, Naqi, Mohammad, Playford, Martin P., Goel, Rishi R., Li, Xiaobai, Biehl, Ann J., Ochoa-Navas, Isabel, Manna, Zerai, Shi, Yinghui, Thomas, Donald, Chen, Jinguo, Biancotto, Angélique, Apps, Richard, Cheung, Foo, Kotliarov, Yuri, Babyak, Ashley L., Zhou, Huizhi, Shi, Rongye, Stagliano, Katie, Tsai, Wanxia Li, Vian, Laura, Gazaniga, Nathalia, Giudice, Valentina, Lu, Shajia, Brooks, Stephen R., MacKay, Meggan, Gregersen, Peter, Mehta, Nehal N., Remaley, Alan T., Diamond, Betty, O’Shea, John J., Gadina, Massimo, Kaplan, Mariana J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185103/
https://www.ncbi.nlm.nih.gov/pubmed/34099646
http://dx.doi.org/10.1038/s41467-021-23361-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185103/
https://www.ncbi.nlm.nih.gov/pubmed/34099646
http://dx.doi.org/10.1038/s41467-021-23361-z

Ejemplares similares